| 1 |
Theofilis P, Oikonomou E, Tsioufis K, Tousoulis D. Diabetes Mellitus and Heart Failure: Epidemiology, Pathophysiologic Mechanisms, and the Role of SGLT2 Inhibitors. Life (Basel) 2023;13. [PMID: 36836854 DOI: 10.3390/life13020497] [Reference Citation Analysis]
|
| 2 |
Xu Y, Kovacic JC. Endothelial to Mesenchymal Transition in Health and Disease. Annu Rev Physiol 2023;85:245-67. [PMID: 36266259 DOI: 10.1146/annurev-physiol-032222-080806] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 3 |
Wang E, Wang H, Chakrabarti S. Endothelial-to-mesenchymal transition: An underappreciated mediator of diabetic complications. Front Endocrinol (Lausanne) 2023;14:1050540. [PMID: 36777351 DOI: 10.3389/fendo.2023.1050540] [Reference Citation Analysis]
|
| 4 |
Sun H, Wang Z, Wang Y, Rong H, Wang D, Liu X, Jin K, Sun Z, Fan Q. Bibliometric and visualized analysis of sodium-Glucose cotransporter 2 inhibitors. Front Pharmacol 2022;13:1009025. [PMID: 36686683 DOI: 10.3389/fphar.2022.1009025] [Reference Citation Analysis]
|
| 5 |
Chen X, Wang J, Lin Y, Liu Y, Zhou T. Signaling Pathways of Podocyte Injury in Diabetic Kidney Disease and the Effect of Sodium-Glucose Cotransporter 2 Inhibitors. Cells 2022;11. [PMID: 36497173 DOI: 10.3390/cells11233913] [Reference Citation Analysis]
|
| 6 |
Packer M. Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy Hypothesis. Circulation 2022;146:1383-405. [PMID: 36315602 DOI: 10.1161/CIRCULATIONAHA.122.061732] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 7 |
Nazer R, Albratty M, Aldhahi MI, Alqurashy M, Halawi MA, Albarrati A. Effect of Dapagliflozin on Exercise Capacity and Cardiovascular Risk in Patients with Heart Failure. Healthcare 2022;10:2133. [DOI: 10.3390/healthcare10112133] [Reference Citation Analysis]
|
| 8 |
Yan Y, Li M, Lin J, Ji Y, Wang K, Yan D, Shen Y, Wang W, Huang Z, Jiang H, Sun H, Qi L. Adenosine monophosphate activated protein kinase contributes to skeletal muscle health through the control of mitochondrial function. Front Pharmacol 2022;13:947387. [DOI: 10.3389/fphar.2022.947387] [Reference Citation Analysis]
|
| 9 |
Wang S, Tian C, Gao Z, Zhang B, Zhao L. Research status and trends of the diabetic cardiomyopathy in the past 10 years (2012–2021): A bibliometric analysis. Front Cardiovasc Med 2022;9:1018841. [DOI: 10.3389/fcvm.2022.1018841] [Reference Citation Analysis]
|
| 10 |
Li J, Zhou L, Gong H. New insights and advances of sodium-glucose cotransporter 2 inhibitors in heart failure. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.903902] [Reference Citation Analysis]
|
| 11 |
Zhan X, Cheng L, Huo N, Yu L, Liu C, Liu T, Li G, Fu H. Sodium–glucose cotransporter-2 inhibitor alleviated atrial remodeling in STZ-induced diabetic rats by targeting TLR4 pathway. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.908037] [Reference Citation Analysis]
|
| 12 |
Hsieh PL, Chu PM, Cheng HC, Huang YT, Chou WC, Tsai KL, Chan SH. Dapagliflozin Mitigates Doxorubicin-Caused Myocardium Damage by Regulating AKT-Mediated Oxidative Stress, Cardiac Remodeling, and Inflammation. Int J Mol Sci 2022;23:10146. [PMID: 36077544 DOI: 10.3390/ijms231710146] [Reference Citation Analysis]
|
| 13 |
Wang H, Ding L, Tian L, Tian Y, Liao L, Zhao J. Empagliflozin reduces diffuse myocardial fibrosis by extracellular volume mapping: A meta-analysis of clinical studies. Front Endocrinol 2022;13:917761. [DOI: 10.3389/fendo.2022.917761] [Reference Citation Analysis]
|
| 14 |
Liu Y, Liu Y, He W, Mu X, Wu X, Deng J, Nie X. Fibroblasts: Immunomodulatory factors in refractory diabetic wound healing. Front Immunol 2022;13:918223. [DOI: 10.3389/fimmu.2022.918223] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 15 |
Elrakaybi A, Laubner K, Zhou Q, Hug MJ, Seufert J. Cardiovascular protection by SGLT2 inhibitors - Do anti-inflammatory mechanisms play a role? Mol Metab 2022;:101549. [PMID: 35863639 DOI: 10.1016/j.molmet.2022.101549] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 16 |
Ma L, Zou R, Shi W, Zhou N, Chen S, Zhou H, Chen X, Wu Y. SGLT2 inhibitor dapagliflozin reduces endothelial dysfunction and microvascular damage during cardiac ischemia/reperfusion injury through normalizing the XO-SERCA2-CaMKII-coffilin pathways. Theranostics 2022;12:5034-50. [PMID: 35836807 DOI: 10.7150/thno.75121] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 17 |
Jing Y, Yang R, Chen W, Ye Q. Anti-Arrhythmic Effects of Sodium-Glucose Co-Transporter 2 Inhibitors. Front Pharmacol 2022;13:898718. [DOI: 10.3389/fphar.2022.898718] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 18 |
Peng M, Xia T, Zhong Y, Zhao M, Yue Y, Liang L, Zhong R, Zhang H, Li C, Cao X, Yang M, Wang Y, Shu Z. Integrative pharmacology reveals the mechanisms of Erzhi Pill, a traditional Chinese formulation, against diabetic cardiomyopathy. J Ethnopharmacol 2022;296:115474. [PMID: 35716918 DOI: 10.1016/j.jep.2022.115474] [Reference Citation Analysis]
|
| 19 |
Peng M, Fu Y, Wu C, Zhang Y, Ren H, Zhou S. Signaling Pathways Related to Oxidative Stress in Diabetic Cardiomyopathy. Front Endocrinol 2022;13:907757. [DOI: 10.3389/fendo.2022.907757] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 20 |
Chu T, Dai C, Li X, Gao L, Yin H, Ge J. Extravascular rapamycin film inhibits the endothelial-to-mesenchymal transition through the autophagy pathway to prevent vein graft restenosis. Biomaterials Advances 2022;137:212836. [DOI: 10.1016/j.bioadv.2022.212836] [Reference Citation Analysis]
|
| 21 |
Feijóo-Bandín S, Aragón-Herrera A, Otero-Santiago M, Anido-Varela L, Moraña-Fernández S, Tarazón E, Roselló-Lletí E, Portolés M, Gualillo O, González-Juanatey JR, Lago F. Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models. Int J Mol Sci 2022;23:5634. [PMID: 35628443 DOI: 10.3390/ijms23105634] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 22 |
Li X, Flynn ER, do Carmo JM, Wang Z, da Silva AA, Mouton AJ, Omoto ACM, Hall ME, Hall JE. Direct Cardiac Actions of Sodium-Glucose Cotransporter 2 Inhibition Improve Mitochondrial Function and Attenuate Oxidative Stress in Pressure Overload-Induced Heart Failure. Front Cardiovasc Med 2022;9:859253. [DOI: 10.3389/fcvm.2022.859253] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 23 |
Theofilis P, Sagris M, Oikonomou E, Antonopoulos AS, Siasos G, Tsioufis K, Tousoulis D. Pleiotropic effects of SGLT2 inhibitors and heart failure outcomes. Diabetes Research and Clinical Practice 2022. [DOI: 10.1016/j.diabres.2022.109927] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 24 |
Liu Z, Liu L, Zhang H, Jiang Y, Wang H, Gupta SK. Preventive Effect Observation of Dapagliflozin on Middle and Later Ventricular Remodeling in Patients with Acute ST Segment Elevation Anterior Wall Myocardial Infarction: A Single-Center, Retrospective Cohort Study. Journal of Healthcare Engineering 2022;2022:1-9. [DOI: 10.1155/2022/3955914] [Reference Citation Analysis]
|
| 25 |
Manolis AA, Manolis TA, Melita H, Manolis AS. Sodium-Glucose Cotransporter Type 2 Inhibitors and Cardiac Arrhythmias. Trends in Cardiovascular Medicine 2022. [DOI: 10.1016/j.tcm.2022.04.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 26 |
da Silva JS, Gonçalves RGJ, Vasques JF, Rocha BS, Nascimento-Carlos B, Montagnoli TL, Mendez-Otero R, de Sá MPL, Zapata-Sudo G. Mesenchymal Stem Cell Therapy in Diabetic Cardiomyopathy. Cells 2022;11:240. [PMID: 35053356 DOI: 10.3390/cells11020240] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 27 |
Tilinca MC, Tiuca RA, Tilea I, Varga A. The SGLT-2 Inhibitors in Personalized Therapy of Diabetes Mellitus Patients. J Pers Med 2021;11:1249. [PMID: 34945721 DOI: 10.3390/jpm11121249] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 28 |
Liu P, Zhang J, Wang Y, Shen Z, Wang C, Chen DQ, Qiu X. The Active Compounds and Therapeutic Target of Tripterygium wilfordii Hook. f. in Attenuating Proteinuria in Diabetic Nephropathy: A Review. Front Med (Lausanne) 2021;8:747922. [PMID: 34621768 DOI: 10.3389/fmed.2021.747922] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 29 |
Winiarska A, Knysak M, Nabrdalik K, Gumprecht J, Stompór T. Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists. Int J Mol Sci 2021;22:10822. [PMID: 34639160 DOI: 10.3390/ijms221910822] [Cited by in Crossref: 10] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 30 |
Gager GM, von Lewinski D, Sourij H, Jilma B, Eyileten C, Filipiak K, Hülsmann M, Kubica J, Postula M, Siller-Matula JM. Effects of SGLT2 Inhibitors on Ion Homeostasis and Oxidative Stress associated Mechanisms in Heart Failure. Biomed Pharmacother 2021;143:112169. [PMID: 34560555 DOI: 10.1016/j.biopha.2021.112169] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 31 |
Tian J, Zhang M, Suo M, Liu D, Wang X, Liu M, Pan J, Jin T, An F. Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AMPKα/TGF-β/Smad signalling in type 2 diabetic rats. J Cell Mol Med 2021;25:7642-59. [PMID: 34169635 DOI: 10.1111/jcmm.16601] [Cited by in Crossref: 24] [Cited by in F6Publishing: 30] [Article Influence: 12.0] [Reference Citation Analysis]
|
